Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04294160 · ClinicalTrials.gov registry record · Phase 1
A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 122
- Enrollment target
NCT04294160 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 122 participants.
The verdict
NCT04294160, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 122 participants
- Enrollment target
Study Summary
A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.
Interventions
- DRUG Trametinib
- DRUG Dabrafenib
- DRUG LXH254
- DRUG LTT462
- DRUG TNO155
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2020-07-22 |
| Est. Completion | 2024-09-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04294160
The ClinicalTrials.gov registry entry for NCT04294160 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Trametinib is the first listed.
NCT04294160 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04294160 about?
NCT04294160 is a clinical study titled "A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer". A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.
What is the current status of trial NCT04294160?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 122 participants. The study started on 2020-07-22. Estimated completion is 2024-09-25.
What interventions are being tested in trial NCT04294160?
The interventions under investigation include: Trametinib (DRUG), Dabrafenib (DRUG), LXH254 (DRUG), LTT462 (DRUG), TNO155 (DRUG).
Who is sponsoring clinical trial NCT04294160?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.